Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.21
- Piotroski Score 3.00
- Grade Outperform
- Symbol (CRVS)
- Company Corvus Pharmaceuticals, Inc.
- Price $9.06
- Changes Percentage (1.34%)
- Change $0.12
- Day Low $8.95
- Day High $9.18
- Year High $10.00
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $13.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.51
- Trailing P/E Ratio -3.98
- Forward P/E Ratio -3.98
- P/E Growth -3.98
- Net Income $-27,029,000
Income Statement
Quarterly
Annual
Latest News of CRVS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ...
CEO Richard Miller discusses the quick response kinetics of ITK inhibition on atopic dermatitis in the earnings call. Initial improvements are expected within a week, with a durable effect similar to ...
By Yahoo! Finance | 1 week ago -
Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) stock price dropped 12% last week; retail investors would not be happy
Retail investors hold the majority of shares in Corvus Pharmaceuticals, Inc. Institutions and hedge funds also have significant ownership. Insider ownership is positive, and the general public holds a...
By Yahoo! Finance | 5 months ago
